Alpha 2.0
Login Register
» Authors » Clive Morris

Clive Morris

Explore the profile of Clive Morris including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 747
Followers 0
Related Specialties
Oncology
General Medicine
Cell Biology
Top 10 Co-Authors
Karen Howarth
Benjamin Besse
Laura Mezquita
David Planchard
Cecile Jovelet
Ludovic Lacroix
Frank De Kievit
Emma Green
Greg Jones
Vincent Plagnol
Published In
JCO Precis Oncol
Clin Cancer Res
PLoS One
J Thorac Oncol
Lung Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy
Popat S, Januszewski A, OBrien M, Ahmad T, Lewanski C, Dernedde U, et al.
Br J Cancer . 2024 Dec; 132(3):245-252. PMID: 39639088
Background: Here we present long-term outcomes of first line afatinib in comorbid patients with suspected or confirmed EGFR mutant NSCLC otherwise considered unsuitable for chemotherapy, and the clinical utility of...
2.
Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial
Hawkey C, Avery A, Coupland C, Crooks C, Dumbleton J, Hobbs F, et al.
Lancet . 2022 Nov; 400(10363):1597-1606. PMID: 36335970
Background: Peptic ulcers in patients receiving aspirin are associated with Helicobacter pylori infection. We aimed to investigate whether H pylori eradication would protect against aspirin-associated ulcer bleeding. Methods: We conducted...
3.
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
Knapp B, Mezquita L, Devarakonda S, Aldea M, Waqar S, Pepin K, et al.
Front Oncol . 2022 Apr; 12:856132. PMID: 35419282
Introduction: Circulating tumor DNA (ctDNA) testing may identify patients at high risk for recurrence following chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). We evaluated the feasibility of...
4.
Recruitment to a large scale randomised controlled clinical trial in primary care: the Helicobacter Eradication Aspirin Trial (HEAT)
Stevenson D, Avery A, Coupland C, Hobbs F, Kendrick D, Moore M, et al.
Trials . 2022 Feb; 23(1):140. PMID: 35164864
Background: The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter (H.) pylori eradication reduces hospitalisation for peptic ulcer bleeding. Recruited participants were...
5.
Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study
Breadner D, Vincent M, Correa R, Black M, Warner A, Sanatani M, et al.
Lung Cancer . 2022 Feb; 165:145-151. PMID: 35124411
Introduction: Blood-based liquid biopsies examining circulating tumour DNA (ctDNA) have increasing applications in non-small cell lung cancer (NSCLC). Limitations in sensitivity remain a barrier to ctDNA replacing tissue-based testing. We...
6.
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
Kim C, Xi L, Cultraro C, Wei F, Jones G, Cheng J, et al.
Cancers (Basel) . 2021 Jul; 13(13). PMID: 34283064
: We assessed whether serial ctDNA monitoring of plasma and saliva predicts response and resistance to osimertinib in EGFR-mutant lung adenocarcinoma. Three ctDNA technologies-blood-based droplet-digital PCR (ddPCR), next-generation sequencing (NGS),...
7.
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting and Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer
Mezquita L, Swalduz A, Jovelet C, Ortiz-Cuaran S, Howarth K, Planchard D, et al.
JCO Precis Oncol . 2020 Sep; 4. PMID: 32923908
Purpose: Liquid biopsy specimen genomic profiling is integrated in non-small-cell lung cancer (NSCLC) guidelines; however, data on the clinical relevance for alterations are scarce. We evaluated the clinical utility of...
8.
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer
Remon J, Lacroix L, Jovelet C, Caramella C, Howarth K, Plagnol V, et al.
JCO Precis Oncol . 2020 Sep; 3. PMID: 32914037
Purpose: To assess the feasibility and utility of circulating tumor DNA (ctDNA) by amplicon-based next-generation sequencing (NGS) analysis in the daily clinical setting in a cohort of patients with advanced...
9.
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with -Mutant Metastatic Non-Small Cell Lung Cancer
Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, et al.
Clin Cancer Res . 2020 Aug; 26(23):6242-6253. PMID: 32859654
Purpose: The limited knowledge on the molecular profile of patients with -mutant non-small cell lung cancer (NSCLC) who progress under BRAF-targeted therapies (BRAF-TT) has hampered the development of subsequent therapeutic...
10.
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
Remon J, Swalduz A, Planchard D, Ortiz-Cuaran S, Mezquita L, Lacroix L, et al.
PLoS One . 2020 Jun; 15(6):e0234302. PMID: 32525942
Circulating tumor DNA (ctDNA)-based molecular profiling is rapidly gaining traction in clinical practice of advanced cancer patients with multi-gene next-generation sequencing (NGS) panels. However, clinical outcomes remain poorly described and...